S937
Clinical - Mixed sites & palliation
ESTRO 2026
Results: The median age of patients was 63 years old (5-94). They had different histological bulky tumours (67% sarcomas, 22% squamous cell carcinoma and 11% medulloblastoma) in different locations (33% head and neck, 22% limbs, 33% abdomen and 11% thorax). 55.56% of them were ECOG 2, 77.78% were classified as stage IV and 66.67% had high-grade tumours. They presented a median follow-up of 11 weeks. All the tumours had long diameters over 7 cm (with a maximum of 31.37 cm) and a median volume of 921 cc (94-3983,6). 100% of patients had an improvement in pain, with a reduction in the VAS from 8 to 2. 78% (n=7) had radiologic partial response (rPR) and 11% (n=1) stable disease (SD). One case (11%) was catalogued as radiologic progression (RP). However, 82.3% of the tumour mass after treatment corresponded to necrotic tissue, being classified as pseudoprogression.
large unresectable tumors: a single institution experience Jorge F. Obeso-Herrera, Alba Lopez-Carmona, Jose Medina-Suarez, Carmen Hernandez-Carrillo-Martinez- Almeida, Elisa F. Salcedo, Andres J. Vera-Rosas, Marta Lloret-Saez-Bravo Radiation Oncology, Dr Negrin University Hospital of Gran Canaria, Las Palmas de Gran Canaria, Spain Purpose/Objective: Bulky and locally advanced tumours usually represent a huge therapeutic challenge in Radiation Oncology, due to their size, location and proximity to other critical structures1. Life quality of patients is often affected by this type of tumours, showing an incomplete response to conventional treatments. Partially ablative body radiotherapy (PABR) offers an alternative which limits toxicity and improves local control1. We have conducted a single-institution study to evaluate the feasibility, safety and early clinical results of PABR in patients treated in our centre. Material/Methods: We conducted a retrospective single-centred study between May 2024 and September 2025 that included nine patients. For contouring, a GTV integrated boost of 50 Gy addressed to the core of the tumour is generated out of the main GTV, using an isometric contraction of 1-1.5 cm. The PTV is generated from the main GTV with a one-centimetre isometric expansion, where a dose of 20 Gy to the periphery of the tumour is prescribed. These doses were administered in five fractions using VMAT and IGRT before each session. The pain was evaluated through a visual analog scale (VAS) and volume control was CT-guided in most patients 3-6 months after the treatment.
Conclusion: Our study shows that PABR can be an accessible and safe treatment tool, with excellent symptomatic and volumetric responses in patients with advanced unresectable tumours. References: Yu, K. K., Yeo, A., Ngan, S., Chu, J., Chang, D., Siva, S., Wong, A., Kron, T., Hardcastle, N., Gaudreault, M., Chesson, T., Williams, S., Burns, M., & Chander, S. (2024). Partially Ablative Body Radiotherapy (PABR): A novel approach for palliative radiotherapy of locally advanced bulky unresectable sarcomas. Radiotherapy And Oncology, 194, 110185. https://doi.org/10.1016/j.radonc.2024.110185. Keywords: PABR, bulky tumour, analgaesia
Made with FlippingBook - Share PDF online